01—Abstract
Summary
Summary of the 10-Q filed March 5, 2012. Cited figures are marked; the original filing is the authoritative source.
Agilent Technologies, Inc. reported strong revenue growth for the three months ended January 31, 2012, with total net revenue increasing by 8% year-over-year to $1.635 billiona.
This growth was driven primarily by robust performance in the Life Sciences and Chemical Analysis segments. Net income also saw a significant increase, rising to $230 millionb from $193 million in the prior year period, reflecting improved operational efficiency and revenue growth. The company generated $150 million in cash from operations, demonstrating solid cash flow generation.
Key strategic developments include the declaration of Agilent's first quarterly dividend of $0.10c per share, signaling a commitment to returning value to shareholders. The company continues to focus on integrating the Varian acquisition, expecting to achieve $100 million in net cost savings, with a significant portion already realized. Looking ahead, Agilent remains focused on delivering market-leading products, optimizing operations, and leveraging opportunities in emerging markets and through strategic acquisitions to drive future growth.
02—Key points
Key Highlights
- Total net revenue increased 8% to $1.635 billion for the three months ended January 31, 2012.
- Net income rose to $230 million ($0.65 diluted EPS) from $193 million ($0.54 diluted EPS) in the prior year period.
- Operating margin improved to 16.6% from 13.9% year-over-year.
- Net cash provided by operating activities was $150 million.
- Agilent declared its first quarterly cash dividend of $0.10 per share.
- Goodwill increased by $39 million primarily due to acquisitions.
- The company reported strong revenue growth in Life Sciences (14%) and Chemical Analysis (14%) segments, while Electronic Measurement saw a more modest 1% increase.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in Q1 FY2012, Agilent Technologies, Inc. kept $0.14.
- Revenue$1.64B100.0%
- Cost of revenue−$761.0M46.5%
- Gross profit$874.0M53.5%
- Operating costs−$603.0M36.9%
- Operating income$271.0M16.6%
- Interest, other & tax−$41.0M2.5%
- Net income$230.0M14.1%
04—Financials
Financial Highlights
Figures from 10-QQ1 FY2012filed March 5, 2012Financial Statements
Q1 FY2012 against Q1 FY2011
| Line item | Q1 FY2012Q1 FY2011 | Change |
|---|---|---|
| Revenue | $1.64B$1.52B | +7.6% |
| Cost of Revenue | $761.00M$703.00M | +8.3% |
| Gross Profit | $874.00M$816.00M | +7.1% |
| R&D Expenses | $162.00M$159.00M | +1.9% |
| SG&A Expenses | $441.00M$446.00M | −1.1% |
| Operating Expenses | $1.36B$1.31B | +4.3% |
| Operating Income | $271.00M$211.00M | +28.4% |
| Interest Expense | $26.00M$23.00M | +13.0% |
| Net Income | $230.00M$193.00M | +19.2% |
| EPS (Basic) | $0.66$0.56 | +17.9% |
| EPS (Diluted) | $0.65$0.54 | +20.4% |
| Shares Outstanding (Basic) | 348.00M347.00M | +0.3% |
| Shares Outstanding (Diluted) | 352.00M355.00M | −0.8% |
05—Questions
Frequently Asked Questions
What was the primary driver of Agilent's revenue growth in this quarter?
Agilent's revenue growth was primarily driven by strong performance in its Life Sciences and Chemical Analysis segments. Specifically, revenue from life sciences products in pharmaceutical markets increased strongly, and demand within academic and government markets also grew. For the Chemical Analysis segment, revenue from all end-markets grew, with particular strength in spectroscopy, consumables, and services.
How did the company's profitability change compared to the previous year?
Profitability improved significantly. Net income increased to $230 million from $193 million in the same period last year. This improvement was supported by an increase in operating margin to 16.6% from 13.9%, attributed to higher revenue and a reduction in variable and incentive pay.
What is the significance of the first-ever cash dividend declared by Agilent?
The declaration of Agilent's first quarterly cash dividend of $0.10 per share on January 17, 2012, signifies a commitment by the company to return capital to its shareholders. This marks a new phase for the company, indicating financial stability and confidence in future performance.
What is the current status of the Varian integration, and what are the expected benefits?
Agilent is actively integrating the Varian acquisition, focusing on revenue and cost synergies. The company expects to achieve $100 million in net cost savings, with approximately one-third already realized by the end of fiscal 2011. Further savings are expected within cost of products and services by 2014. The integration is also aimed at increasing technology sharing between the businesses.
06—Continue